Background Advanced clear cell renal cell carcinoma still lacks reliable diagnostic and
prognostic biomarkers. Recently, tumor vaccines targeting specific molecules have been …

Current treatment strategy for kidney renal clear cell carcinoma (KIRC) is limited. Tumor-
associated antigens, especially neoantigen-based personalized mRNA vaccines represent …

Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy with diverse
histological types. This study aimed to detect neoantigens in ccRCC to develop mRNA …

Increasing evidence has revealed the promise of mRNA-type cancer vaccines as a new
direction for cancer immune treatment in several solid tumors, however, its application in …

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal carcinoma. It is
particularly important to accurately judge the prognosis of patients. Since most tumor …

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer.
Currently, we lack effective risk models for the prognosis of ccRCC patients. Given the …

Kidney renal clear cell carcinoma (KIRC) is the leading cause of kidney cancer-related
deaths. Currently, there are no studies in tumor immunology investigating the use of …

Clear cell renal cell carcinoma (ccRCC) is a prevalent urinary malignancy. Despite the
recent development of better diagnostic tools and therapy, the five-year survival rate for …

Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrates, and many of them
respond to immunotherapy with checkpoint inhibitors including anti-PD-L1 or anti-PD1 …

Increasing evidence has shown that tumor microenvironments are an important feature in
clear cell renal cell carcinoma (ccRCC) carcinogenesis and therapeutic efficacy. In this …